{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gerardin M"],"funding":["Agence Nationale de Sécurité du Médicament et des Produits de Santé"],"pagination":["124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10949610"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["<h4>Background</h4>In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients.<h4>Results</h4>A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were lookin"],"journal":["Orphanet journal of rare diseases"],"pubmed_title":["Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study."],"pmcid":["PMC10949610"],"funding_grant_id":["AAP-2014-009"],"pubmed_authors":["Andreu MR","Harchaoui S","Besancon A","Habibi A","Ngo S","Holvoet L","Victorri-Vigneau C","Carausu L","Lambilliotte A","Noel V","Rohrlich PS","Clouzeau J","Gerardin M","Leon A","Petras M","Gondran G","Driss F","Cerutti D","Divialle-Doumdo L","Kamdem A","Rousselet M","Conde M","Grall-Bronnec M","Aquizerate A","Santin A","Valentin JB","Pluchart C","Cougoul P","Boucher A","Micallef J","Arnaud C","Guitton C","Augusty E","Grados A","Ame S","Abouchahla W","Gibaja V","Jolliet P","Thuret I","Loko G","Dumesnil C","Castex MP","Elenga N","Mattioni S","Chantalat C","Bodet D","N'dizeye S","Nimubona S","Odievre MH","Barrault-Anstett MF","Pierre MH","Alexis-Fardini S","Mornand P","Gardembas M","Ramassamy A","Piguet C","Makowski C","Toutain F","Machin J","PHEDRE Group","Armari C","Simon P","Daveluy A","Ifrim R","Deheul S","Paillard C","Cannas G","Li Thiao Te V","Gauthier A","Roussin A","Minckes O","Passeron A","Haustant-Andry L","Giaccobbi V","Niakate A","Ghnaya H","Eveillard JR","Khalifeh T","Lemonne N","Desbree A","Pain S","French Addictovigilance Network (FAN)","Receveur MC","Authier N","Berceanu A","Merlusca L","Couec ML","Chamouine A","Runel-Belliard C","Colomb-Bottollier E","Graveleau J","Galacteros F","Boutet A","Merlin E","Pondarre C","Feuillet F","Lalande M","Caous AS","Ruivard M","Fouilhe N","Lejars O","Mallard A","Johnson H","Monpoux F","Garou A","Masseau A","Poutrel S","Debbache K","Lahary A","Rose C","Jean E","Navarro R","Billaud M","Djezzar S","Brasme JF","Guichard I","Barrelet A","Fois E","Etienne-Julan M","Le Boisselier R","Peyriere H"],"additional_accession":[]},"is_claimable":false,"name":"Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study.","description":"<h4>Background</h4>In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients.<h4>Results</h4>A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were lookin","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-04T19:15:48.052Z","creation":"2025-04-04T19:15:48.052Z"},"accession":"S-EPMC10949610","cross_references":{"pubmed":["38500184"],"doi":["10.1186/s13023-024-03133-w"]}}